CL-PTL-130 IND 014205 Confidential and proprietary information of Gradalis, Inc. It is the user’s responsibility to verify adequate training before executing a document. Do not make unauthorized copies. COVER PAGE OFFICIAL PROTOCOL TITLE: A Multi -Center Phase III, Randomized, Open -Label Trial of Vigil (b i-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second -Line Regimen for Ewing’s Sarcoma PROTOCOL NUMBER: CL-PTL-130 IND NUMBER: 014205 NCT NUMBER: NCT03495921 STATISTICAL ANALY SIS PLAN VERSION DATE: December 5, 2018 CONFIDENTIAL Information and data included in this protocol contain trade secrets and privileged or confidential information which is the property of Gradalis, Inc. No person is authorized to make it public without written permission of Gradalis, Inc.